Characteristic analysis and comparison of glycolipid metabolism in patients with coronavirus disease 2019 in common condition and severe cases

doi:10.3969/j.issn.1674-8115.2021.03.012

Abstract

Abstract: Objective

·To analyze and compare the characteristics of glycolipid metabolism between common and severe patients with coronavirus disease 2019 (COVID-19).

Methods

·Thirty-six patients with COVID-19 were hospitalized in the general ward of Wuhan Leishenshan Hospital and fifty severe patients with COVID-19 in intensive care unit (ICU) from February to March, 2020. All the patients were divided into two groups: the common patient group and the severe patient group. Their electronic medical records were extracted and analyzed. The demographic data as well as clinical data, laboratory results, comorbidities and clinical outcomes in the two groups were collected and compared by independent sample t test, non-parametric test as well as χ² test. From the metabolic point of view, the characteristics of glucose and lipid metabolism in COVID-19 common and severe patients and the possible related factors for patients staying in ICU were analyzed.

Results

·There was no significant difference between the two groups in terms of gender, number of patients with diabetes and coronary heart disease (CAD). The average age of severe patients was significantly older than that of the common patients (P<0.05). The proportion of the severe patients with hypertension (52.0%) was significantly higher than that of the common patients (22.2%) (P<0.05). The lymphocyte count of the severe patients was significantly lower than that of the common patients (P<0.05). There was no significant difference in glutamic-pyruvic transaminase (GPT), glutamic-oxaloacetic transaminase (GOT), serum creatinine (Scr) and blood uric acid (BUA) between the two groups. Blood serum albumin (ALB), adjusted calcium concentration (Ca_c), total cholesterol (TC), triacylglycerols (TAG), high density lipoprotein (HDL) and the low density lipoprotein (LDL) in the severe patients were significantly lower than those in the common patients (all P<0.05). Fasting blood glucose (FBG) in the severe patients was significantly higher than that in the common patients (P=0.001). Multivariate Logistic regression showed that the increase of FBG and the decrease of TC, HDL, LDL, ALB were related to COVID-19 patients staying in ICU.

Conclusion

·There are deteriorative disorders in terms of glucose and lipid metabolism among the severe patients with COVID-19. The FBG, TC, HDL, LDL and ALB may related to the admission of ICU.

Key words: coronavirus disease 2019 (COVID-19), common patient, severe patient, glycolipid metabolism

CLC Number:

R373.1

Jiang YUE, Yong ZHOU, Hua XU, Wen LIU, Xiao-feng HAN, Qing MAO, Ji-dong ZHANG, Jing MA, Han-dong JIANG, Wei LIU. Characteristic analysis and comparison of glycolipid metabolism in patients with coronavirus disease 2019 in common condition and severe cases[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 355-359.

Figures/Tables 4

TrendMD

References 14

1	Chen Y, Liu QY, Guo DY. Emerging coronaviruses: genome structure, replication, and pathogenesis[J]. J Med Virol, 2020, 92(10): 2249.
2	Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069.
3	Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5):475-481.
4	国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03)[2020-04-30]..
5	Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
6	Li Q, Guan XH, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020, 382(13):1199-1207.
7	Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229): 1033-1034.
8	刘冰, 刘雪菲, 周敏. 关注感染新型冠状病毒的糖尿病患者[J]. 中华内分泌代谢杂志, 2020, 36(3): 195-197.
9	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720.
10	Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062.
11	Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State[J]. JAMA, 2020, 323(16): 1612-1614.
12	Graf CE, Pichard C, Herrmann FR, et al. Prevalence of low muscle mass according to body mass index in older adults[J]. Nutrition, 2017, 34: 124-129.
13	Duc S, Rainfray M, Soubeyran P, et al. Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy[J]. Psychooncology, 2017, 26(1): 15-21.
14	Wu CM, Chen XY, Cai YP, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med, 2020, 180(7): 934-943.

Item	Common group (N=36)	Severe group (N=50)	t/χ²value	P value
Gender/n			0.284	0.416
Male	21	32
Female	15	18
Age/year	52±15	68±12	-5.382	0.000
Diabetes/n (%)	5 (13.9)	10 (20.0)	0.543	0.570
Hypertension/n (%)	8 (22.2)	26 (52.0)	7.764	0.005
CHD/n (%)	2 (5.6)	10 (20.0)	3.637	0.066

Item	Common group (N=36)	Severe group (N=50)	t/χ²value	P value
Gender/n			0.284	0.416
Male	21	32
Female	15	18
Age/year	52±15	68±12	-5.382	0.000
Diabetes/n (%)	5 (13.9)	10 (20.0)	0.543	0.570
Hypertension/n (%)	8 (22.2)	26 (52.0)	7.764	0.005
CHD/n (%)	2 (5.6)	10 (20.0)	3.637	0.066

Index	Common group (N=36)	Severe group (N=50)	t value	P value
Lymphocyte count/(10⁹×L^-1)	1.70±0.67	0.77±0.46	7.096	0.000
GPT/(U·L^-1)	34.74±20.41	81.09±232.68	-1.156	0.251
GOT/(U·L^-1)	25.41±13.91	149.93±615.38	-1.178	0.242
Scr/(μmol·L^-1)	61.46±11.54	61.45±13.06	0.002	0.999
BUA/(mmol·L^-1)	336.49±113.64	289.19±102.99	0.119	0.223
ALB/(g·L^-1)	38.89±3.62	29.69±4.62	9.746	0.000
FBG/(mmol·L^-1)	5.25±1.89	8.25±5.40	-3.359	0.001
Ca_c/(mmol·L^-1)	2.25±0.08	2.19±0.16	2.364	0.031
TC/(mmol·L^-1)	4.55±0.94	3.03±1.16	6.332	0.000
TAG/(mmol·L^-1)	1.73±1.23	1.10±0.92	2.627	0.010
HDL/(mmol·L^-1)	1.21±0.33	0.87±0.35	4.457	0.000
LDL/(mmol·L^-1)	2.69±0.64	1.92±0.70	5.065	0.000

Index	Common group (N=36)	Severe group (N=50)	t value	P value
Lymphocyte count/(10⁹×L^-1)	1.70±0.67	0.77±0.46	7.096	0.000
GPT/(U·L^-1)	34.74±20.41	81.09±232.68	-1.156	0.251
GOT/(U·L^-1)	25.41±13.91	149.93±615.38	-1.178	0.242
Scr/(μmol·L^-1)	61.46±11.54	61.45±13.06	0.002	0.999
BUA/(mmol·L^-1)	336.49±113.64	289.19±102.99	0.119	0.223
ALB/(g·L^-1)	38.89±3.62	29.69±4.62	9.746	0.000
FBG/(mmol·L^-1)	5.25±1.89	8.25±5.40	-3.359	0.001
Ca_c/(mmol·L^-1)	2.25±0.08	2.19±0.16	2.364	0.031
TC/(mmol·L^-1)	4.55±0.94	3.03±1.16	6.332	0.000
TAG/(mmol·L^-1)	1.73±1.23	1.10±0.92	2.627	0.010
HDL/(mmol·L^-1)	1.21±0.33	0.87±0.35	4.457	0.000
LDL/(mmol·L^-1)	2.69±0.64	1.92±0.70	5.065	0.000

Index	β value	OR value	P value	95% CI
FBG	0.417	1.518	0.028	1.045?2.205
TC	-1.236	0.290	0.048	0.085?0.990
HDL	-3.191	0.041	0.029	0.002?0.718
LDL	-1.699	0.183	0.015	0.046?0.723
ALB	0.048	1.049	0.010	1.011?1.088